Prostatype Genomics
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Prostatype Genomics' Newsletter: Initiated clinical use at several U.S. top-ranked hospitals and urology clinics
This issue highlights that the company has a positive commercial outlook for the U.S., where clinical use of Prostatype® has been initiated at several of the top 10-ranked U.S. hospitals/urology clinics within prostate cancer according to publicly available ranking lists. The company recently completed a fully subscribed rights issue of approx. 27.3 MSEK, with the aim to achieve Medicare reimbursement approval commenced sales in the U.S. in 2025.
The newsletter also covers strong published study results in Taiwan and includes a filmed interview with Professor Pierluigi Bove at University Hospital Policlinico Tor Vergata in Rome, Italy.
Content of the newsletter:
- Fully subscribed rights issue of approx. 27.3 MSEK strengthens the company ahead of crucial commercial milestones in the U.S.
- U.S. transaction partner engaged for future steps in the company's business plan
- Strong published study results in Taiwan – opens up opportunities for commercial partnerships in Asia
- Filmed interview with Professor Pierluigi Bove at University Hospital Policlinico Tor Vergata in Rome, Italy
Read the full newsletter and subscribe via this link:
https://bit.ly/progenjun25en
Prostatype Genomics' newsletter is published to offer broader and more in-depth information about the company's operations and progress. It is produced together with the IR communications agency Honeybadger, https://www.honeybadger.se/en/
For more information, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
Email: fredrik.rickman@prostatypegenomics.com
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.
| Datum | 2025-06-23, kl 12:15 |
| Källa | MFN |